Mr. Slavinsky serves as General Counsel and Head of Business Development at Prometheus Biosciences. Previously Mr. Slavinsky was at Takeda where he served as Vice President, Takeda Center for External Innovation and Head, Gastroenterology Business Development, Externalization and Special Projects. Prior to joining Takeda, Chris served in several key roles at Pfizer over a seventeen-year period, including Chief Counsel, Meridian Medical Technologies, Chief Counsel, Essential Health Business Transactions, Chief Counsel, Essential Health R&D, and Chief Counsel, Anti-Infectives. Mr. Slavinsky is a director of Phathom Pharmaceuticals (PHAT), where he also serves on the firm’s audit committee, and was previously a director of ARTham Therapeutics. Mr. Slavinsky received a J.D. from the Washington University in St. Louis School of Law, an M.S. in biochemistry and molecular biology from Thomas Jefferson University, and a B.S. in biochemistry from the State University of New York at Stony Brook.